Copyright ©The Author(s) 2018.
World J Gastroenterol. Jun 21, 2018; 24(23): 2457-2467
Published online Jun 21, 2018. doi: 10.3748/wjg.v24.i23.2457
Figure 1
Figure 1 Vedolizumab targets the α4β7 integrin, preventing leucocyte translocation from the blood into the inflamed gut tissue. MadCAM-1: Mucosal addressin cell adhesion molecule.
Figure 2
Figure 2 Real-world studies with vedolizumab in patients with ulcerative colitis (A) and Crohn’s disease (B): Results at week 14.